MYRIAD GENETICS, INC. (MYGN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 130.70M USD | Liabilities, Current |
| Cash and equivalents | 115.20M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 109.50M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 30.60M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $130.70M | $115.20M | (m) | $109.50M | $30.60M | (m) |
| 2026-03-31 | (m) | $130.20M | $124.40M | (m) | $123.80M | $27.90M | (m) |
| 2025-12-31 | (m) | $133.80M | $149.60M | (m) | $115.30M | $30.60M | (m) |
| 2025-09-30 | (m) | $148.00M | $145.40M | (m) | $118.00M | $31.60M | (m) |
| 2025-06-30 | (m) | $199.90M | $74.40M | (m) | $137.00M | $28.70M | (m) |
| 2025-03-31 | (m) | $151.10M | $91.80M | (m) | $120.40M | $28.30M | (m) |
| 2024-12-31 | $223.60M | $164.10M | $102.40M | $0.00 | $121.20M | $27.50M | 1.36× |
| 2024-09-30 | $225.60M | $154.30M | $99.90M | $0.00 | $125.70M | $26.20M | 1.46× |
| 2024-06-30 | $215.10M | $148.90M | $92.40M | $4.90M | $117.80M | $26.10M | 1.44× |
| 2024-03-31 | $222.40M | $146.10M | $96.90M | $7.40M | $118.10M | $24.60M | 1.52× |
| 2023-12-31 | $255.20M | $155.90M | $132.10M | $8.80M | $114.30M | $22.00M | 1.64× |
| 2023-09-30 | $201.50M | $209.30M | $76.00M | $10.30M | $115.20M | $25.10M | 0.96× |
| 2023-06-30 | $233.30M | $221.10M | $102.80M | $18.80M | $111.70M | $22.50M | 1.06× |
| 2023-03-31 | $197.80M | $143.30M | $53.60M | $25.10M | $119.10M | $21.80M | 1.38× |
| 2022-12-31 | $216.50M | $137.20M | $56.90M | $58.00M | $101.60M | $20.10M | 1.58× |
| 2022-09-30 | $295.40M | $129.10M | $110.70M | $82.50M | $102.20M | $19.60M | 2.29× |
| 2022-06-30 | $314.90M | $119.70M | $105.20M | $99.90M | $109.80M | $15.40M | 2.63× |
| 2022-03-31 | $370.10M | $166.00M | $165.20M | $103.20M | $101.70M | $15.60M | 2.23× |
| 2021-12-31 | $431.10M | $204.30M | $258.40M | $81.40M | $91.30M | $15.30M | 2.11× |
| 2021-09-30 | $459.70M | $203.20M | $295.20M | $70.90M | $93.60M | $18.60M | 2.26× |
| 2021-06-30 | $259.20M | $271.00M | $118.40M | $46.00M | $94.80M | $17.70M | 0.96× |
| 2021-03-31 | $270.20M | $149.00M | $148.90M | $27.20M | $94.10M | $24.60M | 1.81× |
| 2020-12-31 | $240.20M | $145.90M | $117.00M | $33.70M | $89.50M | $27.10M | 1.65× |
| 2020-09-30 | $245.50M | $133.70M | $118.30M | $42.10M | $85.10M | $26.60M | 1.84× |
| 2020-06-30 | $285.90M | $147.00M | $163.70M | $54.10M | $68.10M | $29.10M | 1.94× |
| 2020-03-31 | $284.00M | $113.20M | $121.00M | $60.50M | $102.50M | $30.80M | 2.51× |
| 2019-12-31 | $259.90M | $112.40M | $81.20M | $60.40M | $118.30M | $28.10M | 2.31× |
| 2019-09-30 | $259.60M | $115.40M | $89.90M | $52.70M | $117.00M | $28.10M | 2.25× |
| 2019-06-30 | $270.80M | $117.80M | $93.20M | $43.70M | $133.90M | $31.40M | 2.30× |
| 2019-03-31 | $292.30M | $108.90M | $84.90M | $64.80M | $142.60M | $31.90M | 2.68× |
| 2018-12-31 | $282.00M | $113.30M | $90.60M | $74.80M | $116.60M | $33.30M | 2.49× |
| 2018-09-30 | $286.60M | $108.00M | $93.30M | $74.20M | $119.10M | $35.90M | 2.65× |
| 2018-06-30 | $278.90M | $102.20M | $110.90M | $69.70M | $98.30M | $34.30M | 2.73× |
| 2018-03-31 | $281.00M | $94.30M | $97.40M | $59.90M | $123.70M | $33.40M | 2.98× |
| 2017-12-31 | $264.60M | $159.30M | $88.70M | $54.80M | $121.10M | $38.20M | 1.66× |
| 2017-09-30 | $261.50M | $139.20M | $87.90M | $60.40M | $113.20M | $38.90M | 1.88× |
| 2017-06-30 | $256.30M | $217.50M | $102.40M | $48.30M | $105.60M | $42.20M | 1.18× |
| 2017-03-31 | $286.90M | $221.70M | $123.80M | $48.30M | $114.80M | $47.40M | 1.29× |
| 2016-12-31 | $270.10M | $82.80M | $108.10M | $54.40M | $107.60M | $51.30M | 3.26× |
| 2016-09-30 | $246.60M | $274.90M | $86.90M | $61.50M | $98.20M | $53.90M | 0.90× |
| 2016-06-30 | $250.70M | $72.30M | $68.50M | $90.50M | $91.70M | $38.30M | 3.47× |
| 2016-03-31 | $307.80M | $66.10M | $120.50M | $96.20M | $91.10M | $25.30M | 4.66× |
| 2015-12-31 | $303.60M | $65.90M | $134.70M | $84.60M | $84.30M | $29.10M | 4.61× |
| 2015-09-30 | $238.80M | $59.00M | $87.40M | $68.00M | $83.40M | $34.30M | 4.05× |
| 2015-06-30 | $230.60M | $68.70M | $64.10M | $80.70M | $85.80M | $25.10M | 3.36× |
| 2015-03-31 | $226.63M | $67.17M | $55.21M | $79.22M | $92.19M | $29.36M | 3.37× |
| 2014-12-31 | $246.34M | $59.84M | $59.71M | $105.41M | $81.22M | $20.17M | 4.12× |
| 2014-09-30 | $235.33M | $67.72M | $69.80M | $89.81M | $75.72M | $24.77M | 3.47× |
| 2014-06-30 | $267.76M | $80.58M | $64.82M | $121.64M | $81.30M | $23.92M | 3.32× |
| 2014-03-31 | $294.84M | $72.16M | $85.80M | $126.36M | $82.68M | $18.91M | 4.09× |
| 2013-12-31 | $437.73M | $67.39M | $71.60M | $282.00M | $84.14M | (m) | 6.50× |
| 2013-09-30 | $443.24M | $79.03M | $84.99M | $272.03M | $86.22M | (m) | 5.61× |
| 2013-06-30 | $466.65M | $64.51M | $104.07M | $268.24M | $94.33M | $5.01M | 7.23× |
| 2013-03-31 | $429.33M | $53.62M | $112.32M | $223.83M | $93.17M | $7.14M | 8.01× |
| 2012-12-31 | $434.20M | $45.49M | $68.42M | $290.21M | $75.56M | $10.47M | 9.55× |
| 2012-09-30 | $411.67M | $57.36M | $95.58M | $253.58M | $62.50M | $10.60M | 7.18× |
| 2012-06-30 | $400.97M | $44.97M | $86.35M | $254.18M | $60.44M | $11.57M | 8.92× |
| 2012-03-31 | $388.31M | $37.05M | $104.85M | $232.51M | $50.95M | $10.38M | 10.48× |
| 2011-12-31 | $393.62M | $35.05M | $108.85M | $241.78M | $42.99M | $10.29M | 11.23× |
| 2011-09-30 | $394.34M | $31.29M | $62.68M | $286.85M | $44.82M | $9.70M | 12.60× |
| 2011-06-30 | $396.73M | $34.39M | $52.68M | $293.78M | $50.27M | $5.67M | 11.54× |
| 2011-03-31 | $407.66M | $23.37M | $67.38M | $293.85M | $46.44M | (m) | 17.44× |
| 2010-12-31 | $431.36M | $23.19M | $67.67M | $323.63M | $40.06M | (m) | 18.60× |
| 2010-09-30 | $472.17M | $30.93M | $123.31M | $305.03M | $43.83M | (m) | 15.27× |
| 2010-06-30 | $451.03M | $27.47M | $92.84M | $310.39M | $47.80M | (m) | 16.42× |
| 2010-03-31 | (m) | (m) | $102.15M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $60.43M | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | $91.20M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $63.51M | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $237.73M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |